Christian Görgens, Sven Guddat, Josef Dib, Hans Geyer, Wilhelm Schänzer, Mario Thevis: Mildronate (Meldonium) in professional sports – monitoring doping control urine samples using hydrophilic interaction liquid chromatography – high resolution/high accuracy mass spectrometry. In: Drug Testing and Analysis. 7. Jahrgang, Nr.11–12, 2015, S.973–979, doi:10.1002/dta.1788.
E. Liepinsh, R. Vilskersts u. a.: Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. In: Journal of cardiovascular pharmacology. Band 48, Nummer 6, Dezember 2006, S. 314–319, doi:10.1097/01.fjc.0000250077.07702.23, PMID 17204911.
C. Sesti, B. Z. Simkhovich u. a.: Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. In: Journal of cardiovascular pharmacology. Band 47, Nummer 3, März 2006, S. 493–499, doi:10.1097/01.fjc.0000211732.76668.d2, PMID 16633095.
Yun-Feng Lu, Xin Hu, Kai-Shun Bi: Determination of mildronate in human plasma and urine by liquid chromatography–tandem mass spectrometry. In: Journal of Chromatography B. Band852, Nr.1–2, Juni 2007, S.35–39, doi:10.1016/j.jchromb.2006.12.031.
Yuriy V. Pidpruzhnykov, Valerii E. Sabko, Volodymyr V. Iurchenko, Igor A. Zupanets: UPLC-MS/MS method for bioequivalence study of oral drugs of meldonium. In: Biomedical Chromatography. Band26, Nr.5, Mai 2012, S.599–605, doi:10.1002/bmc.1703.
E. Liepinsh, R. Vilskersts u. a.: Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. In: Journal of cardiovascular pharmacology. Band 48, Nummer 6, Dezember 2006, S. 314–319, doi:10.1097/01.fjc.0000250077.07702.23, PMID 17204911.
C. Sesti, B. Z. Simkhovich u. a.: Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. In: Journal of cardiovascular pharmacology. Band 47, Nummer 3, März 2006, S. 493–499, doi:10.1097/01.fjc.0000211732.76668.d2, PMID 16633095.
Y. Hayashi, T. Kirimoto u. a.: Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. In: European journal of pharmacology. Band 395, Nummer 3, Mai 2000, S. 217–224, PMID 10812052.